Goldman Sachs Ups Sotera Health Target to $24 Amid Analyst's Strong Track Record

Goldman Sachs analyst Evie Koslosky has reaffirmed her buy rating for Sotera Health Company (SHC.US) and increased its target price to $24. This decision comes after reviewing the company's performance. According to TipRanks data, Koslosky has a success rate of 80.0% and an average return of 5.9% over the past year.

Koslosky's rating is not a guarantee of future success, but it suggests that she believes Sotera Health Company has potential for growth. The analyst's ratings are based on her analysis of the company's financials and market trends. While there may be risks involved in investing in SHC.US, Koslosky's buy rating indicates that she sees more opportunities than challenges.

TipRanks is an independent third-party service that provides data on financial analysts' performance. The platform calculates success rates and average returns based on the analysts' recommendations. Koslosky's 80.0% success rate puts her among the top-performing analysts, according to TipRanks data.